Clinical trials · Nashville, TN
Cancer clinical trials in Nashville
We’re tracking 447 recruiting cancer studies with a site in or near Nashville — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Nashville
- NCT05366881Recruiting
Blood test study to spot early cancer signal and cancer leftovers
This observational study checks whether a blood test (a “cfDNA” test) can detect early signs of cancer or small amounts of cancer left after treatment. It may help doctors use a simple blood sample to improve cancer detection and follow-up.
Nashville, TennesseeAges 40 years+ - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for cancers with a KRAS G12D mutation
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT06966024RecruitingPhase 1
Study of DCC-2812 for advanced genitourinary cancers
This trial tests an experimental pill called DCC-2812 for people with advanced kidney, bladder, or prostate cancer. The goal is to see if it is safe and if it might help shrink tumors or slow the cancer's growth.
Nashville, TennesseeAges 18 years+ - NCT04516447RecruitingPhase 1
Testing a new drug for advanced ovarian cancer
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
Nashville, TennesseeAges 18 years+ - NCT04678648RecruitingPhase 1
Testing RSC-1255 in advanced cancers with RAS changes
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Nashville, TennesseeAges 18 years+ - NCT05645536Enrolling by invitationPhase 3
Safety follow-up for hormone-positive, HER2-negative breast cancer
This trial studies the safety of continuing endocrine therapy with ovarian suppression (for women) after you finish the earlier OVELIA study. It may help doctors confirm that the treatment remains safe for longer-term use.
Nashville, TennesseeAges 18–51 - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Nashville, TennesseeAges 1–30 - NCT05693766RecruitingPhase 2
Gene test guides treatment for hormone-positive breast cancer
This trial studies whether a gene-signature test can help guide treatment choices for people with hormone receptor–positive (ER and/or PR) breast cancer that has spread or can’t be fully removed. It may help find the best therapy approach after prior hormone therapy and targeted cancer medicine.
Nashville, TennesseeAges 18 years+ - NCT05734430Recruiting
Study of genetics in appendix cancer families
This study looks at genetic (inherited) and other biological factors in people with appendix cancer and, in some cases, their biological parents. The goal is to learn what may contribute to appendix cancer and help researchers better understand risk.
Nashville, TennesseeAges 18 years+ - NCT07028853RecruitingPhase 3
New drug combo for advanced prostate cancer
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
Nashville, TennesseeAges 18 years+ - NCT05768139RecruitingPhase 1/Phase 2
Testing a new targeted drug for advanced solid tumors with PI3Kα mutation
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
Nashville, TennesseeAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
RAS-targeting drugs for gastrointestinal cancers
This trial tests new drugs that target a specific genetic change (RAS) in gastrointestinal cancers like pancreatic and colorectal cancer. The goal is to see if these drugs can shrink or slow down the cancer.
Nashville, TennesseeAges 18 years+ - NCT07813637RecruitingPhase 1
Testing a combination of two new drugs for advanced prostate cancer
This trial tests two new investigational drugs, JANX013 and JANX007, together in men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination is safe and effective.
Nashville, TennesseeAges 18 years+ - NCT07488923RecruitingPhase 1
ML261 CAR T therapy for advanced small cell lung cancer and related neuroendocrine cancers
This trial tests a new treatment called ML261, which uses your own immune cells (T cells) that have been modified to target DLL3, a protein found on certain cancer cells. It is for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments.
Nashville, TennesseeAges 18 years+ - NCT06995677RecruitingPhase 2
Study of TYRA-300 for bladder cancer that has not spread into muscle
This trial tests a new pill, TYRA-300, for people with a certain type of early-stage bladder cancer that has a specific genetic change (FGFR3). The goal is to see if it can help by targeting the cancer cells and possibly avoiding more invasive treatments.
Nashville, TennesseeAges 18 years+ - NCT05503797RecruitingPhase 2
Study of FORE8394 for cancers with BRAF changes
This trial tests a new drug, FORE8394, for people whose cancers have a change in the BRAF gene. It may be an option if you have a solid tumor or brain tumor that has not responded to other treatments.
Nashville, TennesseeAges 8 years+ - NCT05489211RecruitingPhase 2
Testing a cancer drug for advanced solid tumors
This Phase 2 study tests the drug Dato-DXd (alone or with other cancer medicines) in people with advanced solid tumors. It looks for tumor shrinkage and how safely the treatment can be given.
Nashville, TennesseeAges 18–130 - NCT07044336RecruitingPhase 3
Comparing a new drug to chemo for advanced endometrial cancer
This trial tests a new investigational drug called Puxitatug Samrotecan (AZD8205) against standard chemotherapy in people whose endometrial cancer has come back or spread after prior treatment with platinum chemo and an immunotherapy. The goal is to see if the new drug works better.
Nashville, TennesseeAges 18 years+ - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Nashville, TennesseeAges 18 years+ - NCT07491445RecruitingPhase 3
Daraxonrasib plus chemo for first-line metastatic pancreatic cancer
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
Nashville, TennesseeAges 18 years+ - NCT07491497RecruitingPhase 1/Phase 2
TRI-611 for ALK-positive lung cancer
This study tests an experimental pill for people with a specific type of lung cancer. The trial will see if the drug is safe and if it helps shrink tumors.
Nashville, TennesseeAges 18 years+ - NCT07493512RecruitingPhase 1
Study of xaluritamig for metastatic prostate cancer
This trial tests a new drug called xaluritamig for men with metastatic prostate cancer that is resistant to hormone therapy. It is designed for those who have already tried certain hormone pills and one type of chemotherapy, and aims to see if the drug can shrink tumors or slow cancer growth.
Nashville, TennesseeAges 18 years+ - NCT05683418RecruitingPhase 1
Study of a new drug for PIK3CA-mutated HR+ HER2- breast cancer
This early-stage study tests the safety and tolerability of TOS-358 in women with HR-positive, HER2-negative breast cancer that has a specific gene change (PIK3CA). It may help learn whether this targeted treatment is safe enough to move forward.
Nashville, TennesseeAges 18 years+ - NCT06656390RecruitingPhase 1/Phase 2
Testing ALK201 for advanced solid tumors
This trial tests a new drug, ALK201, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
Nashville, TennesseeAges 18–75
Hear when a new Cancer trial opens near Nashville, TN
We’ll email you when one opens near Nashville, TN — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Nashville
Institutions with a site for the recruiting cancer studies listed above.
- Sarah Cannon Research Institute · 5 studies
- SCRI Oncology Partners · 5 studies
- Vanderbilt University Medical Center · 5 studies
- Research Site · 2 studies
- Tennessee Oncology · 2 studies
- Sarah Cannon Cancer Center
- Sarah Cannon Nashville
- Sarah Cannon, SCRI Oncology Partners
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in Tennessee.
Common questions
- Are there cancer clinical trials near Nashville?
- Yes. We're currently tracking 447 recruiting cancer studies with a site near Nashville, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Nashville?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Nashville to take part?
- Not necessarily. These studies have a site near Nashville, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Nashville regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.